86 related articles for article (PubMed ID: 12359948)
1. N-tert-butyl-N'-(2-cyclohexylamino-5-nitrobenzenesulfonyl)urea, BM531, a dual-acting agent for thromboxane receptor antagonism and thromboxane synthase inhibition.
Michaux C; Dogné JM; Norberg B; Durant F; Masereel B
Acta Crystallogr C; 2002 Oct; 58(Pt 10):o621-3. PubMed ID: 12359948
[TBL] [Abstract][Full Text] [Related]
2. Structure determination and comparison of BM567, a sulfonylurea, with terbogrel, two compounds with dual action, thromboxane receptor antagonism and thromboxane synthase inhibition.
Michaux C; Rolin S; Dogné JM; Durant F; Masereel B; Delarge J; Wouters J
Bioorg Med Chem Lett; 2001 Apr; 11(8):1019-22. PubMed ID: 11327579
[TBL] [Abstract][Full Text] [Related]
3. Terbogrel, a dual-acting agent for thromboxane receptor antagonism and thromboxane synthase inhibition.
Michaux C; Norberg B; Dogné JM; Durant F; Masereel B; Delarge J; Wouters J
Acta Crystallogr C; 2000 Oct; 56 ( Pt 10)():1265-6. PubMed ID: 11025320
[TBL] [Abstract][Full Text] [Related]
4. A pharmacophore model for sulphonyl-urea (-cyanoguanidine) compounds with dual action, thromboxane receptor antagonists and thromboxane synthase inhibitors.
Michaux C; Dogné JM; Rolin S; Masereel B; Wouters J; Durant F
Eur J Med Chem; 2003; 38(7-8):703-10. PubMed ID: 12932901
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
Hanson J; Rolin S; Reynaud D; Qiao N; Kelley LP; Reid HM; Valentin F; Tippins J; Kinsella BT; Masereel B; Pace-Asciak C; Pirotte B; Dogné JM
J Pharmacol Exp Ther; 2005 Apr; 313(1):293-301. PubMed ID: 15626721
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology of the thromboxane receptor antagonist and thromboxane synthase inhibitor BM-531.
Dogné JM; Rolin S; de Leval X; Benoit P; Neven P; Delarge J; Kolh P; Damas J; David JL; Masereel B
Cardiovasc Drug Rev; 2001; 19(2):87-96. PubMed ID: 11484064
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of a sulfonylcyanoguanidine as thromboxane A2 receptor antagonist and thromboxane synthase inhibitor.
Dogné JM; Wouters J; Rolin S; Michaux C; Pochet L; Durant F; Delarge J; Masereel B
J Pharm Pharmacol; 2001 May; 53(5):669-80. PubMed ID: 11370706
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time.
Dogné JM; Hanson J; de Leval X; Kolh P; Tchana-Sato V; de Leval L; Rolin S; Ghuysen A; Segers P; Lambermont B; Masereel B; Pirotte B
J Pharmacol Exp Ther; 2004 May; 309(2):498-505. PubMed ID: 14742735
[TBL] [Abstract][Full Text] [Related]
9. N-tert-butyl-N'-[5-cyano-2-(4-methylphenoxy)phenylsulfonyl]urea, a new TXA₂ receptor antagonist.
Bambi-Nyanguile SM; Mangwala Kimpende P; Pirotte B; Van Meervelt L
Acta Crystallogr C; 2013 Aug; 69(Pt 8):901-3. PubMed ID: 23907886
[TBL] [Abstract][Full Text] [Related]
10. A novel approach to dual-acting thromboxane receptor antagonist/synthase inhibitors based on the link of 1,3-dioxane-thromboxane receptor antagonists and -thromboxane synthase inhibitors.
Ackerley N; Brewster AG; Brown GR; Clarke DS; Foubister AJ; Griffin SJ; Hudson JA; Smithers MJ; Whittamore PR
J Med Chem; 1995 May; 38(10):1608-28. PubMed ID: 7752186
[TBL] [Abstract][Full Text] [Related]
11. Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors.
Soyka R; Guth BD; Weisenberger HM; Luger P; Müller TH
J Med Chem; 1999 Apr; 42(7):1235-49. PubMed ID: 10197967
[TBL] [Abstract][Full Text] [Related]
12. Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 2. Design, synthesis, and evaluation of a novel series of phenyl oxazole derivatives.
Takeuchi K; Kohn TJ; Mais DE; True TA; Wyss VL; Jakubowski JA
Bioorg Med Chem Lett; 1998 Aug; 8(15):1943-8. PubMed ID: 9873463
[TBL] [Abstract][Full Text] [Related]
13. Effect of BM-573 [N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, in a porcine model of acute pulmonary embolism.
Ghuysen A; Lambermont B; Dogné JM; Kolh P; Tchana-Sato V; Morimont P; Magis D; Hanson J; Segers P; D'Orio V
J Pharmacol Exp Ther; 2004 Sep; 310(3):964-72. PubMed ID: 15121765
[TBL] [Abstract][Full Text] [Related]
14. BM-573, a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, prevents pig myocardial infarction induced by coronary thrombosis.
Rolin S; Petein M; Tchana-Sato V; Dogne JM; Benoit P; Lambermont B; Ghuysen A; Kolh P; Masereel B
J Pharmacol Exp Ther; 2003 Jul; 306(1):59-65. PubMed ID: 12721335
[TBL] [Abstract][Full Text] [Related]
15. Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 3. Synthesis and biological activities of oxazolecarboxamide-substituted omega-phenyl-omega-(3-pyridyl)alkenoic acid derivatives and related compounds.
Takeuchi K; Kohn TJ; True TA; Mais DE; Wikel JH; Utterback BG; Wyss VL; Jakubowski JA
J Med Chem; 1998 Dec; 41(27):5362-74. PubMed ID: 9876106
[TBL] [Abstract][Full Text] [Related]
16. The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 is a more potent inhibitor of platelet function than aspirin.
Fontana P; Alberts P; Sakariassen KS; Bounameaux H; Meyer JP; Santana Sorensen A
J Thromb Haemost; 2011 Oct; 9(10):2109-11. PubMed ID: 21777369
[No Abstract] [Full Text] [Related]
17. Thromboxane modulating agents. 3. 1H-imidazol-1-ylalkyl- and 3-pyridinylalkyl-substituted 3-[2-[(arylsulfonyl)amino]ethyl]benzenepropanoic acid derivatives as dual thromboxane synthase inhibitor/thromboxane receptor antagonists.
Dickinson RP; Dack KN; Long CJ; Steele J
J Med Chem; 1997 Oct; 40(21):3442-52. PubMed ID: 9341919
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological profile and therapeutic potential of BM-573, a combined thromboxane receptor antagonist and synthase inhibitor.
Ghuysen A; Dogné JM; Chiap P; Rolin S; Masereel B; Lambermont B; Kolh P; Tchana-Sato V; Hanson J; D'Orio V
Cardiovasc Drug Rev; 2005; 23(1):1-14. PubMed ID: 15867944
[TBL] [Abstract][Full Text] [Related]
19. Syntheses and bioactivities of novel carbamates combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI).
Fujita M; Seki T
Bioorg Med Chem Lett; 2002 May; 12(10):1383-6. PubMed ID: 11992782
[TBL] [Abstract][Full Text] [Related]
20. Thromboxane receptors antagonists and/or synthase inhibitors.
Davì G; Santilli F; Vazzana N
Handb Exp Pharmacol; 2012; (210):261-86. PubMed ID: 22918735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
